TrialBMC medicine2025

Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.

Jinhong Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.